New drug cocktail shows promise for Tough-to-Treat endometrial cancer
NCT ID NCT03008408
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether adding ribociclib to a standard two-drug regimen (everolimus and letrozole) works better for people with advanced or recurrent endometrial cancer. About 90 participants will be randomly assigned to receive either the two-drug or three-drug combination. The goal is to see if the three-drug combo improves clinical benefit (tumor shrinkage or stable disease).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- everolimus, letrozole, and ribociclib
- What this could lead to
- If successful, this could lead to a more effective combination treatment for advanced or recurrent endometrial cancer, potentially slowing disease progression.
- What could go wrong
- This is a phase II trial with only 90 participants, so results are preliminary. Adding ribociclib may increase side effects without improving outcomes, and the benefit may not apply to all types of endometrial cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lyndon Baines Johnson General Hospital
Houston, Texas, 77026-1967, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted pill aims to halt recurrent ovarian and endometrial cancers
- Hormone blockers join forces against Treatment-Resistant endometrial cancer
- Hormone blocker plus targeted drug shows promise against tough uterine cancer
- Cancer drug combo tested for rare gene mutation – but trial stopped early
- New drug duo shows promise for Tough-to-Treat endometrial cancer
- Custom-Made cancer vaccine shows promise in advanced tumors